⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374623 | 0.75 | — | — | |
| SCHEMBL29427127 | 0.75 | — | — | |
| SCHEMBL165105 | 0.75 | — | — | |
| SCHEMBL2112692 | 0.75 | — | — | |
| SCHEMBL198155 | 0.75 | CRHR1 (0.38) | — | |
| SCHEMBL232179 | 0.75 | — | — | |
| SCHEMBL31514804 | 0.75 | — | — | |
| SCHEMBL16493300 | 0.75 | — | — | |
| SCHEMBL47044 | 0.75 | — | — | |
| SCHEMBL8266802 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096453-A1 | COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-113072542-B | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-112204024-B | ERK inhibitor and application thereof | 贝达药业股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11466013-B2 | ERK inhibitor and use thereof | BETTA PHARMACEUTICALS CO., LTD (CN) | 2022-10-11 | — | — | US | disclosed |
| US-11466013-B2 | ERK inhibitor and use thereof | BETTA PHARMACEUTICALS CO., LTD (CN) | 2022-10-11 | — | — | US | disclosed |
| CN-113072542-A | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业有限公司 | 2021-07-06 | — | — | CN | disclosed |
| WO-2021097039-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-3805217-A1 | ERK INHIBITOR AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2021-04-14 | — | — | EP | disclosed |
| EP-3805217-A1 | ERK INHIBITOR AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2021-04-14 | — | — | EP | disclosed |
| WO-2021032033-A1 | PYRIDAZINOL COMPOUND, DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | 青岛清原化合物有限公司 | 2021-02-25 | — | — | WO | disclosed |
| EP-2419405-A1 | 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS | Theravance, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120910-A1 | 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS | THERAVANCE, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010120910-A1 | 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS | THERAVANCE, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267743-A1 | 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267743-A1 | 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267743-A1 | 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-10-21 | — | — | US | disclosed |
| WO-2009117421-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008076046-A1 | NOVEL 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076044-A1 | NOVEL 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007058602-A2 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, NEURODEGENERATION AND DEMENTIA. | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |